Eupraxia Pharmaceuticals Inc. (EPRX)
EPRX Stock Price Chart
Explore Eupraxia Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze EPRX price movements and trends.
EPRX Company Profile
Discover essential business fundamentals and corporate details for Eupraxia Pharmaceuticals Inc. (EPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Apr 2024
Employees
49.00
Website
https://www.eupraxiapharma.comCEO
James A. Helliwell
Description
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Financial Timeline
Browse a chronological timeline of Eupraxia Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.25.
Earnings released on 12 May 2026
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 12 Mar 2026
EPS came in at -$0.37 falling short of the estimated -$0.16 by -131.25%.
Earnings released on 4 Nov 2025
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%.
Earnings released on 12 Aug 2025
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%.
Earnings released on 6 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%.
Earnings released on 20 Mar 2025
EPS came in at -$0.21 falling short of the estimated -$0.18 by -16.67%.
Earnings released on 7 Nov 2024
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.05%.
Earnings released on 7 Aug 2024
EPS came in at -$0.17 falling short of the estimated -$0.17 by -0.37%.
Earnings released on 8 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.25%.
Earnings released on 21 Mar 2024
EPS came in at -$0.15 , while revenue for the quarter reached $2.98m .
Earnings released on 30 Sept 2023
EPS came in at -$0.25 falling short of the estimated -$0.11 by -124.05%.
Earnings released on 30 Jun 2023
EPS came in at -$0.36 falling short of the estimated -$0.27 by -30.95%.
Earnings released on 31 Mar 2023
EPS came in at -$0.23 falling short of the estimated -$0.17 by -34.38%.
Earnings released on 31 Dec 2022
EPS came in at -$0.41 falling short of the estimated -$0.13 by -225.81%.
Earnings released on 30 Sept 2022
EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.96%.
Earnings released on 30 Jun 2022
EPS came in at -$0.31 falling short of the estimated -$0.30 by -3.72%.
Earnings released on 31 Mar 2022
EPS came in at -$0.26 .
Earnings released on 31 Dec 2021
EPS came in at -$0.30 falling short of the estimated -$0.27 by -10.30%.
Earnings released on 30 Sept 2021
EPS came in at -$0.35 .
EPRX Stock Performance
Access detailed EPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
